276 related articles for article (PubMed ID: 27294160)
1. The Emerging Role of HMGB1 in Neuropathic Pain: A Potential Therapeutic Target for Neuroinflammation.
Wan W; Cao L; Khanabdali R; Kalionis B; Tai X; Xia S
J Immunol Res; 2016; 2016():6430423. PubMed ID: 27294160
[TBL] [Abstract][Full Text] [Related]
2. HMGB1 as a potential therapeutic target for neuropathic pain.
Maeda T; Ozaki M; Kobayashi Y; Kiguchi N; Kishioka S
J Pharmacol Sci; 2013; 123(4):301-5. PubMed ID: 24285082
[TBL] [Abstract][Full Text] [Related]
3. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation.
Nogueira-Machado JA; Volpe CM; Veloso CA; Chaves MM
Expert Opin Ther Targets; 2011 Aug; 15(8):1023-35. PubMed ID: 21585289
[TBL] [Abstract][Full Text] [Related]
4. Targeting high mobility group box protein 1 ameliorates testicular inflammation in experimental autoimmune orchitis.
Aslani F; Schuppe HC; Guazzone VA; Bhushan S; Wahle E; Lochnit G; Lustig L; Meinhardt A; Fijak M
Hum Reprod; 2015 Feb; 30(2):417-31. PubMed ID: 25452436
[TBL] [Abstract][Full Text] [Related]
5. Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington's disease.
Angelopoulou E; Paudel YN; Piperi C
J Mol Med (Berl); 2020 Mar; 98(3):325-334. PubMed ID: 32036391
[TBL] [Abstract][Full Text] [Related]
6. HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development.
Abdulahad DA; Westra J; Limburg PC; Kallenberg CG; Bijl M
Autoimmun Rev; 2010 Aug; 9(10):661-5. PubMed ID: 20546955
[TBL] [Abstract][Full Text] [Related]
7. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer.
Ohmori H; Luo Y; Kuniyasu H
Expert Opin Ther Targets; 2011 Feb; 15(2):183-93. PubMed ID: 21204727
[TBL] [Abstract][Full Text] [Related]
8. RAGE and TLRs: relatives, friends or neighbours?
Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
[TBL] [Abstract][Full Text] [Related]
9. Expression of the receptor for advanced glycation end products, a target for high mobility group box 1 protein, and its role in chronic recalcitrant rhinosinusitis with nasal polyps.
Dzaman K; Szczepanski MJ; Molinska-Glura M; Krzeski A; Zagor M
Arch Immunol Ther Exp (Warsz); 2015 Jun; 63(3):223-30. PubMed ID: 25503556
[TBL] [Abstract][Full Text] [Related]
10. Extracellular high-mobility group box 1 protein (HMGB1) as a mediator of persistent pain.
Agalave NM; Svensson CI
Mol Med; 2015 Feb; 20(1):569-78. PubMed ID: 25222915
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue.
Casula M; Iyer AM; Spliet WG; Anink JJ; Steentjes K; Sta M; Troost D; Aronica E
Neuroscience; 2011 Apr; 179():233-43. PubMed ID: 21303685
[TBL] [Abstract][Full Text] [Related]
12. High-mobility group box-1 in sterile inflammation.
Tsung A; Tohme S; Billiar TR
J Intern Med; 2014 Nov; 276(5):425-43. PubMed ID: 24935761
[TBL] [Abstract][Full Text] [Related]
13. Disulfide-containing high mobility group box-1 promotes N-methyl-D-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal neurons.
Balosso S; Liu J; Bianchi ME; Vezzani A
Antioxid Redox Signal; 2014 Oct; 21(12):1726-40. PubMed ID: 24094148
[TBL] [Abstract][Full Text] [Related]
14. High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.
Chirico V; Lacquaniti A; Salpietro V; Munafò C; Calabrò MP; Buemi M; Arrigo T; Salpietro C
Eur J Pediatr; 2014 Sep; 173(9):1123-36. PubMed ID: 24809802
[TBL] [Abstract][Full Text] [Related]
15. Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development.
Zurolo E; Iyer A; Maroso M; Carbonell C; Anink JJ; Ravizza T; Fluiter K; Spliet WG; van Rijen PC; Vezzani A; Aronica E
Brain; 2011 Apr; 134(Pt 4):1015-32. PubMed ID: 21414994
[TBL] [Abstract][Full Text] [Related]
16. Multi-walled carbon nanotube induces nitrative DNA damage in human lung epithelial cells via HMGB1-RAGE interaction and Toll-like receptor 9 activation.
Hiraku Y; Guo F; Ma N; Yamada T; Wang S; Kawanishi S; Murata M
Part Fibre Toxicol; 2016 Mar; 13():16. PubMed ID: 27026438
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of miR-381 relieves neuropathic pain development via targeting HMGB1 and CXCR4.
Zhan LY; Lei SQ; Zhang BH; Li WL; Wang HX; Zhao B; Cui SS; Ding H; Huang QM
Biomed Pharmacother; 2018 Nov; 107():818-823. PubMed ID: 30142543
[TBL] [Abstract][Full Text] [Related]
18. Impact of HMGB1, RAGE, and TLR4 in Alzheimer's Disease (AD): From Risk Factors to Therapeutic Targeting.
Paudel YN; Angelopoulou E; Piperi C; Othman I; Aamir K; Shaikh MF
Cells; 2020 Feb; 9(2):. PubMed ID: 32046119
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of HMGB1, toll-like receptor and RAGE in human Rasmussen's encephalitis.
Luan G; Gao Q; Zhai F; Chen Y; Li T
Epilepsy Res; 2016 Jul; 123():36-49. PubMed ID: 27108105
[TBL] [Abstract][Full Text] [Related]
20. HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi.
Ahrens I; Chen YC; Topcic D; Bode M; Haenel D; Hagemeyer CE; Seeba H; Duerschmied D; Bassler N; Jandeleit-Dahm KA; Sweet MJ; Agrotis A; Bobik A; Peter K
Thromb Haemost; 2015 Nov; 114(5):994-1003. PubMed ID: 26202300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
